Skip to main content
S&P 5007,666.45+0.19%DOW50,926.56+0.04%NASDAQ26,871.60+0.04%BTC$84,519.00+0.95%ETH$2,691.89+0.32%GOLD$4,207.80+0.13%OIL$92.91+0.04%
Smart Investors Daily
SID Premium
NK

NASDAQ · NKTR

Nektar Therapeutics

Healthcare · Biotechnology

$60.55

Down-$13.56 (-22.39%)

Updated Oct 1, 2026, 9:35 PM

SID Score

3.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.04B
P/E ratio
-8.02
Dividend yield
0.00%
52-week range
$54.13 – $109.00
Volume
1.21M
Avg. volume
882.67K

Price performance · NKTR

NKTR price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Sep 30, 2026

NKTR closed at $60.55 after 20 trading sessions, down 16.77% for the selected period.

Last close
$60.55
Period change
-16.77%
Period low
$57.06
Period high
$76.37
Daily close
View OHLC price history
NKTR OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 30, 2026$59.96$62.3999$58.91$60.5451.21M
Sep 29, 2026$60.14$60.75$57.69$59.241.82M
Sep 28, 2026$57.00$61.40$56.40$60.401.38M
Sep 25, 2026$59.77$60.98$57.04$57.062.64M
Sep 24, 2026$58.03$61.79$56.21$59.382.8M
Sep 23, 2026$60.40$60.9999$56.92$57.661.84M
Sep 22, 2026$67.08$68.33$59.44$60.973.32M
Sep 21, 2026$68.53$69.84$66.71$66.84766.9K
Sep 18, 2026$68.00$69.09$66.98$67.102.81M
Sep 17, 2026$67.95$69.505$67.34$68.361.26M
Sep 16, 2026$67.00$67.65$65.8501$67.38986.12K
Sep 15, 2026$68.10$68.48$65.75$66.641.26M
Sep 14, 2026$70.00$70.00$68.03$68.50920.05K
Sep 11, 2026$71.41$71.41$68.35$69.76784.21K
Sep 10, 2026$72.01$73.50$70.60$70.65945.89K
Sep 9, 2026$75.10$75.6275$72.00$73.32941.85K
Sep 8, 2026$74.10$77.755$74.00$75.44867.67K
Sep 4, 2026$74.67$75.63$73.64$74.19607.43K
Sep 3, 2026$73.41$76.63$72.99$76.37691.27K
Sep 2, 2026$72.38$74.7201$70.7043$72.74353.96K

Latest NKTR news

The latest Smart Investors Daily articles mentioning NKTR.

Stock researchCompany · Overview

NKTR research

Overview

Company profile and research snapshot.

Company profile

Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$121.00
Implied upside
—
Analysts
—
NKTR recent ratings
DateFirmRatingTarget
Sep 28, 2026BTIGBuy—
Sep 25, 2026BTIGBuy—
Sep 23, 2026WedbushNeutral—
Sep 16, 2026BTIGBuy—
Sep 9, 2026BTIGBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 28, 2026

Nektar Announces Three Oral Presentations for Rezpegaldesleukin at the European Academy of Dermatology & Venereology (EADV) Congress 2026

Nektar Therapeutics (Nasdaq: NKTR) announced today that data from its Phase 2b studies of rezpegaldesleukin in atopic dermatitis and alopecia areata will be presented in three separate oral presentations at the European Academy of Dermatology & Venereology (EADV) Congress 2026, to take place September 30 to October 3, 2026, in Vienna, Austria.

Yahoo · Sep 28, 2026

Nektar Therapeutics (NKTR) Dropped, So What Is Driving Attention Now?

Nektar Therapeutics (NKTR) has drawn fresh attention after recent share price swings, with the stock down 4% over the past day and 21% over the past month on available return data. At a share price of US$57.06, Nektar Therapeutics has swung sharply lower in the short term, with the 7 day share price return down 14.63% and the 30 day share price return down 21.32%. However, the year to date share price return remains up 31.41%, hinting that recent weakness follows a stronger run earlier in the...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By